Focal adhesion kinase (FAK) is overexpressed in many cancers and is involved in a multitude of oncogenic processes and resistance mechanisms. This Review discusses the rationale and preclinical evidence for FAK-based combination therapies and strategies for future development.
- John C. Dawson
- Alan Serrels
- Margaret C. Frame